Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Zacks News
5 Companies That Consistently Beat Earnings Estimates
by Jeffrey Hymen
Companies that are constantly able to defeat its earnings projections usually exhibit effective management, stronger upward momentum, and more impressive future outlooks.
Amgen's Myeloma Drug Improves Overall Survival in Phase III
by Zacks Equity Research
Biotech major, Amgen, Inc. (AMGN) announced final data from the phase III ASPIRE study, which showed that a combination regimen of its drug, Kyprolis, significantly improved overall survival (OS) in patients with relapsed multiple myeloma.
Biotech Stock Roundup: Arena Shoots Up on Study Data, CELG Inks Immuno-Oncology Deal
by Arpita Dutt
Arena (ARNA) saw it shares shoot up on mid-stage data on its pulmonary arterial hypertension drug while quite a few companies provided regulatory updates.
Zacks.com featured highlights: Sanderson Farms, American Woodmark, Vertex Pharmaceuticals, Baxter International and A. O. Smith
by Zacks Equity Research
Zacks.com featured highlights: Sanderson Farms, American Woodmark, Vertex Pharmaceuticals, Baxter International and A. O. Smith
5 Top Multibagger Biotech Stocks to Buy in the 2nd Half
by Tirthankar Chakraborty
Draconian crackdown on drug prices easing out and likelihood of a series of buyouts will help innovation starved biotech companies to gain in the second half.
Here's Why Investors Are Glued to Vertex Pharma (VRTX) Stock
by Zacks Equity Research
Vertex Pharmaceuticals, Inc. (VRTX), has been attracting investor attention.
Fresh Capital to Be Injected into Biotech Stocks: 5 Must-Buys
by Tirthankar Chakraborty
IBB surged 17% since Trump's win but is still down 23% from its all-time intraday high scaled in the July of 2015.
Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt
by Arpita Dutt
Key highlights in the biotech sector include positive data on Clovis' (CLVS) PARP inhibitor, Rubraca.
Zacks.com featured highlights: Etsy, Live Nation Entertainment, Salesforce.com, Vertex Pharmaceuticals and NeoGenomics
by Zacks Equity Research
Zacks.com featured highlights: Etsy, Live Nation Entertainment, Salesforce.com, Vertex Pharmaceuticals and NeoGenomics
5 Toxic Stocks to Discard or Play Short for Profit
by Zacks Equity Research
If you can pinpoint the toxic stocks accurately, you may gain by resorting to an investing strategy called short selling.
Zacks.com featured highlights: Salesforce.com, Vertex Pharmaceuticals, Live Nation Entertainment, Covanta Holding and Etsy
by Zacks Equity Research
Zacks.com featured highlights: Salesforce.com, Vertex Pharmaceuticals, Live Nation Entertainment, Covanta Holding and Etsy
5 Toxic Stocks to Offload or Play Short for Profit
by Zacks Equity Research
Just like identifying stocks with growth potential, spotting toxic stocks and abandoning them at the right time is the key to protect your portfolio from big losses or make profits by short selling them.
Why Is Vertex (VRTX) Up 2.1% Since the Last Earnings Report?
by Zacks Equity Research
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data
by Arpita Dutt
Key highlights in the biotech sector include FDA approval for Regeneron's (REGN) Kevzara and data from Amgen and Celgene.
Concert Pharma Falls After Clinical Hold on Hair Loss Drug
by Zacks Equity Research
Concert Pharmaceuticals, Inc. (CNCE) shares were down almost 8% on Wednesday after the company announced that the FDA has placed a clinical hold on a mid-stage study evaluating its pipeline candidate CTP-543 for the treatment of alopecia areata.
Vertex Ups Kalydeco Sales View as FDA Okays Label Expansion
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated???s (VRTX) announced that the FDA has approved its lead marketed drug, Kalydeco (ivacaftor) for expanded use.
Zacks.com featured highlights: Covanta Holding, PTC, Etsy, Vertex Pharmaceuticals and Live Nation Entertainment
by Zacks Equity Research
Zacks.com featured highlights: Covanta Holding, PTC, Etsy, Vertex Pharmaceuticals and Live Nation Entertainment
5 Toxic Stocks to Steer Clear Of or Play Short Right Now
by Zacks Equity Research
High price of the toxic stocks can be ascribed to an irrational exuberance associated with them or some serious fundamental lacunae. Presence of such stocks in your portfolio may result loss of wealth.
Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal
by Arpita Dutt
Quite a few deals were announced this week including by companies like Biogen (BIIB).
Why Is Vertex Pharma (VRTX) Stock Soaring This Year?
by Zacks Equity Research
Vertex Pharmaceuticals, Inc.'s (VRTX) shares have risen 57.8% this year so far, outperforming the increase of 1.3% for the Zacks classified Large-Cap Pharma industry.
Vertex (VRTX) Q1 Earnings Top, CF Products Sales Strong
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated (VRTX) reported first-quarter 2017 earnings per share of 13 cents (including the impact of stock-based compensation expense), which beat the Zacks Consensus Estimate of 4 cents.
What's in Store for Nivalis (NVLS) this Earnings Season?
by Zacks Equity Research
Nivalis Therapeutics, Inc. (NVLS) is expected to report first-quarter 2017 results early next month. Last quarter, the company had a positive surprise of 9.09%.
Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug
by Arpita Dutt
Focus this week remained on Biogen's (BIIB) first quarter results which surpassed expectations.
What's in Store for Vertex (VRTX) this Earnings Season?
by Zacks Equity Research
Vertex Pharmaceuticals, Inc. (VRTX) is scheduled to report first-quarter 2017 results on Apr 27, after the market closes.
5 Toxic Stocks to Shun or Play Short Right Now
by Zacks Equity Research
Just like picking up stocks with strong growth potential, pinpointing toxic stocks and abandoning them at the right time is the key to protect your portfolio from big losses or make profits by short selling them.